An evaluation of the effectiveness of perampanel in people with epilepsy who have previously undergone resective surgery and/or implantation of a vagal nerve stimulator
dc.contributor.author | Davis Jones, G | |
dc.contributor.author | Stavropoulos, Ioannis | |
dc.contributor.author | Ibrahim, K | |
dc.contributor.author | Tristram, M | |
dc.contributor.author | Neale, M | |
dc.contributor.author | Jory, Caryn | |
dc.contributor.author | Adcock, J | |
dc.contributor.author | Esposito, M | |
dc.contributor.author | Hamandi, K | |
dc.contributor.author | Shankar, Rohit | |
dc.contributor.author | Rugg-Gunn, F | |
dc.contributor.author | Elwes, R | |
dc.contributor.author | Sen, Arjune | |
dc.date.accessioned | 2021-05-22T18:48:13Z | |
dc.date.issued | 2021-03 | |
dc.identifier.issn | 1525-5050 | |
dc.identifier.issn | 1525-5069 | |
dc.identifier.other | 107738 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/17164 | |
dc.description.abstract |
About 30% of people with epilepsy (PWE) are drug-resistant. Those with focal seizures may be suitable for epilepsy surgery. Those not amenable to resective surgery can be considered for vagus nerve stimulation (VNS). However, after operative procedures, around 50% of patients continue to experience seizures. A multi-center retrospective study assessing perampanel effectiveness and tolerability for PWE who have undergone surgical resection and/or VNS implantation was performed. The primary outcome was ≥50% reduction in seizure frequency while secondary outcomes included side effects (SEs), dose-related effectiveness, and toxicity. The median perampanel dose was 6 mg. Only one PWE became seizure free. A ≥50% decrease in seizure frequency was observed in 52.8% of the post-resection group and 16.9% of the VNS group (p < 0.001), while SEs were seen in 44.8% and 41.1%, respectively. Perampanel doses greater than 8 mg led to better response in both groups, especially in the post-VNS cohort. SEs were not dose-related and the safety profile was similar to previous observational studies. Perampanel can be beneficial in these two super-refractory epilepsy groups, particularly in PWE with seizures after surgical resection. Doses of more than 8 mg appear to be well tolerated and may be more effective than lower doses in PWE after surgical interventions. | |
dc.format.extent | 107738-107738 | |
dc.format.medium | Print-Electronic | |
dc.language | en | |
dc.language.iso | eng | |
dc.publisher | Elsevier BV | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Anti-seizure medication | |
dc.subject | Epilepsy surgery | |
dc.subject | Pharmacoresistant epilepsy | |
dc.subject | Seizures | |
dc.subject | VNS | |
dc.title | An evaluation of the effectiveness of perampanel in people with epilepsy who have previously undergone resective surgery and/or implantation of a vagal nerve stimulator | |
dc.type | journal-article | |
dc.type | Journal Article | |
dc.type | Research Support, Non-U.S. Gov't | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000617709000020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.volume | 116 | |
plymouth.publication-status | Published | |
plymouth.journal | Epilepsy & Behavior | |
dc.identifier.doi | 10.1016/j.yebeh.2020.107738 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Users by role | |
dc.publisher.place | United States | |
dcterms.dateAccepted | 2020-12-19 | |
dc.rights.embargodate | 9999-12-31 | |
dc.identifier.eissn | 1525-5069 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1016/j.yebeh.2020.107738 | |
rioxxterms.licenseref.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
rioxxterms.licenseref.startdate | 2021-03 | |
rioxxterms.type | Journal Article/Review |